SCHEMBL269539

SCHEMBL269539

CC(O)CN(Cc1cccc(C(=O)Nc2sc3c(c2C(=O)NN=Cc2ccc(F)cc2)CCC3)c1)CC(C)O

nearest known ligand 0.51

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 8/20 0.51
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
MAPT P10636 4/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
FLT3 P36888 1/20 0.44
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL269538 1.00 SLC34A2 (0.51) SLC34A2NPC1RAB9AMEN1KMT2A
SCHEMBL265629 0.98 SLC34A2 (0.53) SLC34A2NPC1RAB9AMEN1KMT2A
SCHEMBL265630 0.98 SLC34A2 (0.53) SLC34A2NPC1RAB9AMEN1KMT2A
SCHEMBL266023 0.93 SLC34A2 (0.51) SLC34A2NPC1RAB9AMEN1KMT2A
SCHEMBL266024 0.93 SLC34A2 (0.51) SLC34A2NPC1RAB9AMEN1KMT2A
SCHEMBL267494 0.93 SLC34A2 (0.50) SLC34A2NPC1RAB9AMEN1KMT2A
SCHEMBL267495 0.93 SLC34A2 (0.50) SLC34A2NPC1RAB9AMEN1KMT2A
SCHEMBL268954 0.92 SLC34A2 (0.52) SLC34A2NPC1RAB9AMEN1KMT2A
SCHEMBL268955 0.92 SLC34A2 (0.52) SLC34A2NPC1RAB9AMEN1KMT2A
SCHEMBL273826 0.92 SLC34A2 (0.52) SLC34A2NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885NPC1 102/4885RAB9A 883/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885NPC1 115/4885RAB9A 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.